Elixirgen is a biopharmaceutical company specializing in regenerative and rejuvenative medicine: stem cell biology.. The firm is currently developing therapies for chromosome abnormalities such as Down syndrome, telomere diseases, muscular dystrophies, and aging-associated diseases as well as treatments for cell rejuvenation. In May 2016, Elixirgen entered into a license agreement with the National Institute on Aging (NIA), a division of the National Institutes of Health (NIH). The agreement involves several patents that fortify Elixirgenâs existing patent portfolios regarding the gene ZSCAN4 enabling the firm to develop, manufacture, and market research reagents that are based on that gene. The reagents are used to treat pluripotent stem cells, such as embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs). The technologies behind these patents were co-invented by Elixirgenâs co-founder and chief scientific officer, while he served as senior investigator and section chief at the Intramural Research Program, the internal research program of the NIH. The firm also had previously entered into licensing agreements with Keio University in Tokyo and Sumitomo Dainippon Pharma Co., Ltd., a major pharmaceutical company in Jap
